Alejandra Gurtman

机构：Pfizer (United States), Pfizer (United Kingdom) · ORCID：0000-0003-3469-1201

发表论文 146 篇 · 总被引 28949 次 · h-index 44

代表论文

• Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons (2025 · Clinical Infectious Diseases · 被引 60)
• Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine (2025 · New England Journal of Medicine · 被引 33)
• Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults (2025 · Vaccines · 被引 17)
• A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults (2025 · Vaccines · 被引 11)
• A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old (2025 · Vaccine · 被引 9)
• Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age (2025 · Vaccines · 被引 9)